Here, let me fix that for you: Nonsense. If you are referring to K-OC, he ran it to better characterize the drug and to aid in determining what drug combos and CAs it might work with and on. The trial has nothing to do with establishing a MTD, or anything beyond more frequent dosing. If that really was a concern, it would be a much larger trial with a new escalation protocol. There are only two dosages and all dosing is well below the MAD.
News 
Market Data 
Discover 
